The study would aim to analyze the scope of actions to improve access by low income people to some life saving drugs. It concentrates on the problems of access by the poor in India to life saving drugs from Indian pharmaceutical companies. Our key objective would to understand the current failure of accessibility and affordability of poor to life saving drugs and to analyze the scope within market structure for improvement. There are very low levels of government funding for health care in India, with less than 4% of total government resources being allocated to health services. Less than a quarter of health care expenditure is funded by the government while nearly 80% of expenditure is funded privately, mostly through out-of-pocket payments. Thus, the burden for funding health care falls heavily on households. This study would provide insight on how Govt. could directly provide help for the same issue of accessibility and affordability. The national laboratories and academic institutions in the country will have to come forward to take new and more aggressive research initiatives and play a major role to bring in the next revolution in the Indian pharmaceutical sector to ensure affordable healthcare is maintained as a right of all. In this report, we put forward some possible resolutions to the issue of improving access of the poor to essential medicines. Health care in India should be the core focus of the central and state governments in India.